Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

PartnershipapprovedbexobrutidegPositive

AI Analysis

Summary

Nurix Therapeutics and Roche announced HSR clearance and closing of their global collaboration agreement to co-develop and co-commercialize bexobrutideg, a potential best-in-class BTK degrader, across malignant hematology, immunology, and neurology indications.

Outcome Details

HSR clearance received; global collaboration agreement closing

Importance:7/10

Sentiment:

0.70

PartnershipCollaborationBTK DegraderCo-developmentCo-commercializationHSR ClearanceRegulatory Approval

Related Companies

$NRIX $RHHBY

Read the original article

Published by GlobeNewswire Pharma on July 21, 2026 8:01 PM

Read Original